Rapid health technology assessment of Aidi injection combined with first-line chemotherapy for non-small cell lung cancer

XU Congcong; HUANG Liulü; TANG Jiao; LIU Ying; HAN Yonglong

doi:10.6039/j.issn.1001-0408.2023.10.18

您当前的位置：

首页 >

文章列表页 >

Rapid health technology assessment of Aidi injection combined with first-line chemotherapy for non-small cell lung cancer

更新时间：2025-09-27

- Rapid health technology assessment of Aidi injection combined with first-line chemotherapy for non-small cell lung cancer
- ZHONGGUO YAOFANG Vol. 34, Issue 10, Pages: 1247-1251(2023)
- 作者机构：
  
  上海交通大学医学院附属第六人民医院药剂科，上海　201306
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.10.18
  CLC： R979.1
- Received：29 August 2022，
  
  Revised：2023-03-24，
  
  Accepted：12 April 2023，
  
  Published：30 May 2023
- 稿件说明：
移动端阅览
许聪聪,黄柳绿,唐姣,等.艾迪注射液联合一线化疗用于NSCLC的快速卫生技术评估[J].中国药房,2023,34(10):1247-1251.

XU Congcong,HUANG Liulü,TANG Jiao,et al.Rapid health technology assessment of Aidi injection combined with first-line chemotherapy for non-small cell lung cancer[J].ZHONGGUO YAOFANG,2023,34(10):1247-1251.
许聪聪,黄柳绿,唐姣,等.艾迪注射液联合一线化疗用于NSCLC的快速卫生技术评估[J].中国药房,2023,34(10):1247-1251. DOI： 10.6039/j.issn.1001-0408.2023.10.18.

XU Congcong,HUANG Liulü,TANG Jiao,et al.Rapid health technology assessment of Aidi injection combined with first-line chemotherapy for non-small cell lung cancer[J].ZHONGGUO YAOFANG,2023,34(10):1247-1251. DOI： 10.6039/j.issn.1001-0408.2023.10.18.

摘要

目的

评价艾迪注射液联合一线化疗用于非小细胞肺癌（NSCLC）的有效性、安全性和经济性，为临床用药和决策提供循证依据。

方法

计算机检索 PubMed、Embase、the Cochrane Library、中国知网、万方数据、维普网及国内外卫生技术评估（HTA）机构官方网站，收集艾迪注射液联合一线化疗用于NSCLC的 HTA报告、系统评价/Meta分析和药物经济学研究，检索时限均为建库起至2022年8月。资料提取和质量评价后，对纳入研究的结果进行描述性分析。

结果

共纳入16篇文献，其中1篇系统评价，13篇Meta分析，2篇药物经济学研究。与一线化疗相比，艾迪注射液联合一线化疗可提高NSCLC患者的有效率和疾病控制率，延长生存时间，改善生存质量，降低恶心呕吐、白细胞减少、血小板降低发生率，提高免疫功能，但对肝肾功能的影响存在争议。以2019 年全国人均国内生产总值设定支付阈值，艾迪注射液联合一线化疗具有经济性。

结论

艾迪注射液联合一线化疗用于NSCLC的疗效和安全性均较好，且具有一定的经济性，但鉴于纳入的药物经济学研究较少，因此所得经济学结论需谨慎解读。

Abstract

OBJECTIVE

To evaluate the effectiveness， safety and economics of Aidi injection combined with first-line chemotherapy for non-small cell lung cancer （NSCLC）， and to provide evidence-based reference for clinical drug use and decision.

METHODS

Retrieved from PubMed， Embase， the Cochrane Library， CNKI， Wanfang databases， VIP and Health Technology Assessment （HTA） related websites， HTA reports， systematic evaluation/meta-analysis and economic evaluations about Aidi injection combined with first-line chemotherapy for NSCLC were collected from the inception to Aug. 2022. After data extraction and quality evaluation， descriptive analysis was performed for the results of included studies.

RESULTS

A total of 16 pieces of literature were included， involving 1 piece of systematic review， 13 pieces of meta-analysis， 2 pieces of pharmacoeconomic studies. Compared with first-line chemotherapy， Aidi injection combined with first-line chemotherapy could improve response rate and disease control rate， prolonged survival time， improved survival quality， reduced the incidence of nausea and vomiting， leukocytopenia and thrombocytopenia， and improved immune function， but had controversial effects on liver and kidney function. With the payment threshold set by 3 times the national per capita GDP in 2019， Aidi injection combined with first-line chemotherapy had a more economical probability.

CONCLUSIONS

Aidi injection combined with first-line chemotherapy for NSCLC has good efficacy and safety， and has certain economic benefits. However， given the limited pharmacoeconomic studies included， the economic conclusions obtained need to be carefully interpreted.

关键词

Keywords

references

SUNG H ， FERLAY J ， SIEGEL R L ， et al . Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2021 ， 71 （ 3 ）： 209 - 249 .

伍家鸣，王菁，林丽珠，等 . 艾迪注射液联合一线化疗方案治疗非小细胞肺癌临床疗效的Meta分析 [J ] . 中成药， 2017 ， 39 （ 6 ）： 1323 - 1328 .

CHEN W . Cancer statistics：updated cancer burden in China [J ] . Chin J Cancer Res ， 2015 ， 27 （ 1 ）： 1 .

中华医学会肿瘤学分会，中华医学会杂志社 . 中华医学会肿瘤学分会肺癌临床诊疗指南： 2021版 [J ] . 中华肿瘤杂志， 2021 ， 43 （ 6 ）： 591 - 621 .

LIU Y Y ， ZHANG Y ， FENG G L ， et al . Comparison of effectiveness and adverse effects of gefitinib，erlotinib and icotinib among patients with non-small cell lung cancer：a network meta-analysis [J ] . Exp Ther Med ， 2017 ， 14 （ 5 ）： 4017 - 4032 .

XIAO Z ， WANG C Q ， ZHOU M H ， et al . Clinical efficacy and safety of Aidi injection plus paclitaxel-based chemotherapy for advanced non-small cell lung cancer：a meta-analysis of 31 randomized controlled trials following the PRISMA guidelines [J ] . J Ethnopharmacol ， 2019 ， 228 ： 110 - 122 .

唐惠林，门鹏，翟所迪 . 药物快速卫生技术评估方法及应用 [J ] . 临床药物治疗杂志， 2016 ， 14 （ 2 ）： 1 - 4 .

HAILEY D . Toward transparency in health technology assessment：a checklist for HTA reports [J ] . Int J Technol Assess Health Care ， 2003 ， 19 （ 1 ）： 1 - 7 .

SHEA B J ， REEVES B C ， WELLS G ， et al . AMSTAR 2：a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions，or both [J ] . BMJ ， 2017 ， 358 ： j4008 .

HUSEREAU D ， DRUMMOND M ， AUGUSTOVSKI F ， et al . Consolidated Health Economic Evaluation Reporting Standards 2022（CHEERS 2022）statement：updated reporting guidance for health economic evaluations [J ] . BMC Health Serv Res ， 2022 ， 22 （ 1 ）： 114 .

韩燕鸿，揭珂，张荷 . 艾迪注射液辅助GP方案治疗非小细胞肺癌的系统评价 [J ] . 中国实验方剂学杂志， 2016 ， 22 （ 10 ）： 188 - 193 .

杨金菊，丁敏 . 艾迪联合吉西他滨及顺铂治疗晚期非小细胞肺癌的Meta分析 [J ] . 中国全科医学， 2012 ， 15 （ 24 ）： 2794 - 2798 .

王权，何曦冉，田金徽，等 . 艾迪联合紫杉醇和顺铂治疗晚期非小细胞肺癌的Meta分析 [J ] . 中国肺癌杂志， 2010 ， 13 （ 11 ）： 1027 - 1034 .

吴炳辰，徐力，陈敏 . 艾迪注射液联合NP方案治疗晚期非小细胞肺癌的Meta分析 [J ] . 浙江中西医结合杂志， 2009 ， 19 （ 7 ）： 446 - 447 .

呼研 . 艾迪注射液联合吉西他滨及顺铂治疗非小细胞肺癌的Meta分析 [D ] . 沈阳：辽宁中医药大学， 2019 .

赵华叶，李国辉，戚姝娅，等 . 艾迪注射液联合紫杉醇和顺铂治疗中晚期非小细胞肺癌疗效和安全性的Meta分析 [J ] . 中国药房， 2016 ， 27 （ 9 ）： 1210 - 1213 .

WANG J ， LI G C ， YU L L ， et al . Aidi injection plus platinum-based chemotherapy for stage ⅢB/Ⅳ non-small cell lung cancer：a meta-analysis of 42 RCTs following the PRISMA guidelines [J ] . J Ethnopharmacol ， 2018 ， 221 ： 137 - 150 .

ZHAO H Y ， ZHOU H Y ， WANG Y T ， et al . Assessment on the efficacy and safety of aidi injection combined with vinorelbine and cisplatin for treatment of advanced non-small cell lung cancer [J ] . Chin Med J（Engl）， 2016 ， 129 （ 6 ）： 723 - 730 .

XIAO Z ， WANG C Q ， SUN Y P ， et al . Can Aidi injection restore cellular immunity and improve clinical efficacy in non-small-cell lung cancer patients treated with platinum-based chemotherapy? A meta-analysis of 17 randomized controlled trials following the PRISMA guidelines [J ] . Medicine（Baltimore）， 2016 ， 95 （ 44 ）： e5210 .

XIAO Z ， JIANG Y ， WANG C Q ， et al . Clinical efficacy and safety of aidi injection combination with vinorelbine and cisplatin for advanced non-small-cell lung carcinoma：a systematic review and meta-analysis of 54 randomized controlled trials [J ] . Pharmacol Res ， 2020 ， 153 ： 104637 .

XIAO Z ， WANG C Q ， LI L H ， et al . Clinical efficacy and safety of aidi injection plus docetaxel-based chemotherapy in advanced nonsmall cell lung cancer：a meta-analysis of 36 randomized controlled trials [J ] . Evid Based Complement Alternat Med ， 2018 ， 2018 ： 7918258 .

XIAO Z ， WANG C Q ， CHEN L ， et al . Has aidi injection the attenuation and synergistic efficacy to gemcitabine and cisplatin in non-small cell lung cancer? A meta-analysis of 36 randomized controlled trials [J ] . Oncotarget ， 2017 ， 8 （ 1 ）： 1329 - 1342 .

赵鹏 . 吉非替尼联用艾迪注射液治疗非小细胞肺癌的安全性、有效性及经济性评价 [D ] . 广州：暨南大学， 2020 .

张海明 . 中药注射剂辅助治疗非小细胞肺癌的临床疗效及经济学评价 [J ] . 现代肿瘤医学， 2016 ， 24 （ 11 ）： 1742 - 1744 .

王云霞 . 抗肿瘤复方中药注射剂应用分析 [J ] . 中国民族民间医药， 2021 ， 30 （ 10 ）： 33 - 35 .

Views

247

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Pharmacoeconomic evaluation of iruplinalkib therapy for advanced ALK-positive non-small cell lung cancer

Cost-utility analysis of benmelstobart plus anlotinib and chemotherapy as first-line treatment for extensive-stage small cell lung cancer

Pharmacoeconomic evaluation of finerenone combined with standard treatment regimen in the treatment of diabetic nephropathy

Cost-utility analysis of sugemalimab combined with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma with high PD-L1 expression

Pharmacoeconomic evaluation of Bacillus Calmette-Guérin for post-TUR-BT perfusion therapy in patients with intermediate- to high-risk non-muscle invasive bladder cancer in China

Related Author

WANG Hong

LI Haonan

ZHANG Hui

LIU Yuhang

XU Yeyou

WENG Kaiyuan

GAO Ning

GAO Shengnan

Related Institution

Health Economics and Promotion Research Center， Guangdong Pharmaceutical University

International Research Center for Medicinal Administration， Peking University

School of Pharmaceutical Sciences， Peking University

School of Medical Business， Guangdong Pharmaceutical University

Hebei Provincial Association for Comprehensive Evaluation of Medicines and Health Technologies

⁰